A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma Clinical Trial

— STOP-PC  

Official title:

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06079346
• Other study ID #: OT-01-P201
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: May 1, 2024
• Est. completion date: June 1, 2027

Study information

• Verified date: May 2024
• Source: Mateon Therapeutics
• Contact: Cynthia Lee, PhD
• Phone: (650) 635-7024
• Email: clee[@]oncotelic.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.

Description:

OT-01-P201 is designed as a randomized, open-label, active controlled, multicenter Phase 2B/Phase 3 study designed to compare the efficacy and safety of OT-101 in combination with modified FOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to modified FOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer. The primary endpoint of the study is overall survival and key secondary endpoints are progression-free survival and objective response rate.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 455
• Est. completion date: June 1, 2027
• Est. primary completion date: June 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. A diagnosis of advanced and unresectable or metastatic pancreatic adenocarcinoma confirmed by:

1. Histopathology from primary tumor in pancreas, OR

2. Histopathology from a non-pancreatic lesion in the presence of a mass in the pancreas consistent with pancreatic adenocarcinoma or a medically documented history of pancreatic adenocarcinoma.

2. Measurable disease per RECIST v.1.1

3. Male or non-pregnant, non-lactating female, =18 years or age

1. If a female patient is of child-bearing potential, as evidenced by menstrual periods, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [ß- hCG]) documented prior to the first administration of stud drugs

2. Female patients of childbearing age and women < 12 months since the onset of menopause must agree to use acceptable contraceptive methods for the duration of the study and 9 months following the last injection of OT-101.

3. Male patients must use effective contraception for a duration of 6 months after the final dose, as per the prescribing information for oxaliplatin.

4. Provide signed written informed consent

5. Eastern Cooperative Group (ECOG) Performance Status (PS) score of 0-1

6. Willingness and ability to comply with study requirements

7. Patient has adequate organ function by the following laboratory assessments at baseline(obtained =28 days prior to Randomization):

Hematologic

• Platelets =100×109/L

• Hemoglobin =9.0 g/dL

• Absolute Neutrophil Count (ANC) =1.5×109/L

• Patient has acceptable coagulation values obtained =28 days prior to Randomization as demonstrated by prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT) =1.5× upper limit of normal (ULN) (if on Coumadin, patient must be changed to LMWH or on Factor II or Xa anticoagulant with a t½ of less than 24 hours

Hepatic

• Aspartate transaminase (AST)/alanine transaminase (ALT) =3×ULN (if liver metastases are present, =5×ULN)

• Alkaline phosphatase =2.0×ULN (if liver metastases are present, =5×ULN)

• Total bilirubin =2.0×ULN (in patients with Gilbert's Syndrome total bilirubin < or = 2.5xULN)

Renal

• Calculated creatinine clearance =50 mL/min. Actual body weight should be used for calculating creatinine clearance (e.g., using the Modification of Diet in Renal Disease [MDRD] formula. For patients with a body mass index (BMI) >30 kg/m2, lean body weight should be used instead

8. Patient must have a life expectancy of =3 months in the opinion of the Investigator

Exclusion Criteria:

1. Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma (ie,lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinoma

2. Patient has experienced a decrease in ECOG PS between Screening visit and within 72 hours prior to Randomization

3. Patient on Coumadin and not willing to change to LMWH or oral Factor II or Xa inhibitor with t½ of less than 24 hours

4. History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (eg, breast and prostate) for which the patient has been disease-free for at least 3 years. Patients with prior cancer that is adequately controlled per the judgement of the Investigator will not be excluded from the study

5. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for the study

6. Patients with abnormal electrocardiogram (ECG) at baseline (QT or QTc interval >470 ms) will be excluded from this study. The eligibility of patients with ventricular pacemakers for whom the QT interval may not be accurately measurable will be determined on a case-by-case basis by the Sponsor's medical representative in consultation with the principal investigator.

7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics

8. Known history of positivity (regardless of immune status) for human immunodeficiency virus(HIV)

9. Known history of chronic active or active viral hepatitis A, B, or C infection

10. Clinically significant bleeding within 2 weeks prior to Randomization (eg, gastrointestinal[GI] bleeding or intracranial hemorrhage)

11. Pregnant or lactating women

12. Myocardial infarction, coronary bypass surgery, or arterial thromboembolic events within the last 6 months prior to Randomization, symptomatic congestive heart failure (New York Heart Association Classification >Class II, unstable angina, or unstable cardiac arrhythmia requiring medication

13. Clinically significant ascites defined as requiring =1 paracentesis every 2 weeks

14. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to Randomization or anticipated surgery during the study period

15. Prior history of receiving immune checkpoint inhibitors (anti-CTLA4, anti-PD1, anti-PD-L1)

16. Peripheral neuropathy (>Grade 1)

17. Known history of dihydropyrimidine dehydrogenase deficiency (DPD) - Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU). Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity

18. History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegner´s granulomatosis, Sjogren´s syndrome, Bell´s palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, except for psoriasis not requiring systemic therapy, vitiligo or alopecia areata, or hypothyroidism

19. Patients receiving any of the following medications are not eligible for study:

1. Investigational agents other than the protocol drugs

2. Anti-coagulants (except for heparin to maintain the patency of central venous catheters)

3. Non-steroidal anti-inflammatory drugs

4. Clopidogrel (Plavix), dipyridamole (Persantine), or any other drug that inhibits platelet functions

5. Patients on greater than 2 mg dexamethasone, 10 mg Prednisone or or equivalent dose in alternate corticosteroid daily or actively undergoing corticosteroid dose escalation are NOT eligible

20. History of allergic reactions or known hypersensitivity to compounds of similar chemical or biologic composition to OT-101 such as anti-sense oligonucleotides or siRNA

21. Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy. Telemedicine visits are acceptable

22. Not willing and able to comply with study requirements including protocol mandated procedures and visits

23. Other contraindications as defined in the product label of the components of the mFOLFIRINOX treatment regimen

24. Participation in another investigational clinical trial within 30 days of receiving the last dose of investigational study drug

25. Clinically significant psychiatric disorders, legal incapacity or limited legal capacity

26. Patients with a primary immunodeficiency

27. Patients with active central nervous system (CNS) metastases. (Patients with adequately treated CNS metastases who are clinically stable for at least 6 weeks after discontinuation of corticosteroids may be eligible for enrollment with the approval of the Sponsor's medical representative and the principal investigator)

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma

Intervention

Drug:
• OT-101
OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-ß2 gene
• mFOLFIRINOX
Folinic acid, 5-FU, Irinotecan, Oxaliplatin

Locations

Country	Name	City	State
United States	Karmanos Cancer Center	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Oncotelic Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	To compare the efficacy of OT-101 in combination with mFOLFIRINOX versus mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer as measured by overall survival (OS)	2.5 years
Secondary	Pharmacokinetic (PK) Parameter - Area Under the Curve (AUC)	To characterize the area under the curve (AUC) of OT-101 when it is combined with mFOLFIRINOX in patients with advanced and unresectable or metastatic pancreatic cancer. Area under the curve is a measure of how much a drug reaches a person's bloodstream in a given period of time after a dose is given.	1 year
Secondary	Pharmacokinetic (PK) Parameter - Cmax	To characterize the Cmax of OT-101 when it is combined with mFOLFIRINOX in patients with advanced and unresectable or metastatic pancreatic cancer. Cmax is the highest concentration of a drug in the blood, cerebrospinal fluid, or target organ after a dose is given.	1 year
Secondary	Progression-Free Survival (PFS)	To assess the efficacy of OT-101 in combination with mFOLFIRINOX in patients with advanced and unresectable or metastatic pancreatic cancer as measured by Progression-free survival (PFS)	2.5 years
Secondary	Objective Response Rate (ORR)	To assess the efficacy of OT-101 in combination with mFOLFIRINOX in patients with advanced and unresectable or metastatic pancreatic cancer as measured by Objective Response Rate (ORR)	2.5 years
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	To compare the incidence of treatment-emergent adverse events of OT-101 in combination with mFOLFIRINOX versus mFOLFIRINOX alone	2.5 years